PTPN11 gain-of-function mutation is the most common mutation found in patients with juvenile myelomonocytic leukemia and DNMT3A loss occurs in over 20% of acute myeloid leukemia patients. We studied the combined effect of both Ptpn11 gain-offunction mutation (D61Y) and Dnmt3a haploinsufficiency on mouse hematopoiesis, the presence of which has been described in both juvenile myelomonocytic leukemia and acute myeloid leukemia patients. Double mutant mice rapidly become moribund relative to any of the other genotypes, which is associated with enlargement of the spleen and an increase in white blood cell counts. An increase in the mature myeloid cell compartment as reflected by the presence of Gr1 + Mac1 + cells was also observed in double mutant mice relative to any other group. Consistent with these observations, a significant increase in the absolute number of granulocyte macrophage progenitors (GMPs) was seen in double mutant mice. A decrease in the lymphoid compartment including both T and B cells was noted in the double mutant mice. Another significant difference was the presence of extramedullary erythropoiesis with increased erythroid progenitors in the spleens of Dnmt3a +/− ;D61Y mice relative to other groups. Taken together, our results suggest that the combined haploinsufficiency of Dnmt3a and presence of an activated Shp2 changes the composition of multiple hematopoietic lineages in mice relative to the individual heterozygosity of these genes.
INTRODUCTION
Loss of DNA methyltransferase 3A (DNMT3A) activity has been shown to lead to hematopoietic stem cell differentiation defects and the development of myeloid malignancies. DNMT3A is commonly mutated in myeloid diseases, with mutations found in over 20% of all acute myeloid leukemia (AML) patients [1] , in 8% of myelodysplastic syndrome (MDS) patients [2] , and in smaller frequencies in other leukemias. For AML patients, 60% of those with a DNMT3A mutation are heterozygous at Arginine 882 (R882), a dominant negative mutation that results in less than 80% protein activity [3] . The remaining patients usually demonstrate a compound heterozygous or homozygous mutation.
In contrast to AML, individuals with clonal hematopoiesis commonly bear a loss-of-function mutation in only one copy of DNMT3A [4] . In this pre-leukemic state, almost all DNMT3A mutations are nonsynonymous, truncating, or splicing, and mutations in R882 are rare [5] .
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These otherwise healthy individuals are at an increased risk of developing MDS/AML due to acquisition of a second driver mutation [6] and tend to have a poor overall prognosis [1] . Thus, although DNMT3A protein function must be almost completely lost in order to cause malignancy [7] , heterozygous loss-of-function mutations are often found combined with a driver mutation in the development of frank leukemia. Furthermore, Dnmt3a haploinsufficiency alone with no other lesions is sufficient for mice to develop myeloid malignancies when aged to 18-24 months [8] .
Here, we studied the effects of Dnmt3a haploinsufficiency combined with Ptpn11
D61Y
, a gain-offunction mutation in the protein tyrosine phosphatase SHP2, which is the most commonly mutated gene in juvenile myelomonocytic leukemia (JMML) and is used as a mouse model of myeloproliferative disease [9] . Concurrent mutations in both DNMT3A and PTPN11, albeit rare, have been reported in AML [10, 11] and in JMML patients [12] . JMML is an aggressive myeloproliferative neoplasm (MPN) of early childhood with no effective chemotherapeutic treatment and a poor prognosis. ;D61Y mice showed obvious splenomegaly and the spleen to body weight percentage was significantly increased compared to the other three genotypes ( Figure 1A ). In addition to splenomegaly, the double mutant mice also showed significantly higher peripheral blood WBC counts compared to WT or Dnmt3a +/− mice ( Figure 1B ). Flow cytometric analysis of the spleen and peripheral blood to assess the frequency of Gr1 +
RESULTS

We crossed
Mac1
+ myeloid cells revealed a significantly higher percentage of these mature myeloid cells in the Dnmt3a
+/−
;D61Y mice compared to WT and Dnmt3a +/− mice in the spleen, and compared to WT mice in the peripheral blood (Figure 2A-2D ). In contrast, the myeloid cell frequencies in the single mutant mice were not statistically different from WT mice except for D61Y mice in the peripheral blood ( Figure 2C and 2D). The absolute number of Gr1 +
Mac1
+ cells were also significantly greater in double mutant mice relative to the WT and Dnmt3a +/− mice ( Figure 2E ). In contrast to the increase in myeloid cells, the T and B cells were decreased in the spleen and peripheral blood of Dnmt3a
;D61Y mice relative to other groups ( Figure 3A and 3B).
In an effort to explain the increase in mature myeloid cells in the double mutant mice, we performed flow cytometric analysis on bone marrow cells from all four genotypes to assess the number of granulocyte macrophage progenitors (GMPs). As seen in Figure 4 , Dnmt3a
;D61Y mice showed a significant increase in the absolute number of GMPs compared to WT and Dnmt3a +/− mice. The double mutant mice also had significantly more absolute numbers of megakaryocyte erythrocyte progenitors (MEPs) compared to WT mice, but no significant differences in common myeloid progenitors (CMPs) were observed among any of the four groups (Figure 4) . The double mutant mice also showed signs of anemia, with significant decreases in peripheral red blood cell counts, hemoglobin levels, as well as hematocrits relative to WT mice ( Figure  5A -5C). Consistent with these observations, within the erythroid lineage, the CD36 + CD71
+ erythroid progenitors (EPs) were significantly increased in the spleens of the Dnmt3a
;D61Y mice, suggesting compensatory erythropoiesis ( Figure 5D and 5E). Although EP frequency was not increased in the Dnmt3a
;D61Y bone marrow compartment (data not shown), the increased splenic erythropoiesis may explain the increased bone marrow MEP numbers.
DISCUSSION
AML patients often have complete loss of DNMT3A enzyme activity, but its role when only partially inhibited and in combination with a second driver mutation of leukemia is not known. Here we show that mice with heterozygous loss of Dnmt3a combined with a gainof-function Shp2 mutation, D61Y, develop more rapid disease progression and earlier mortality. Mice expressing Shp2D61Y do not usually succumb to leukemia until 45 weeks after induction of expression [9] and mice with Dnmt3a haploinsufficiency do not develop disease until approximately 80 weeks [8] . We found that mice with the two mutations together become moribund much earlier at 24 weeks, indicating that they cooperate to promote myeloid leukemia progression and to shorten survival.
The most marked phenotypic changes we observed in the Dnmt3a
;D61Y mice were splenomegaly, mature myeloid cell expansion in the periphery as well as increased GMPs in the bone marrow. These mice also exhibited signs of anemia, perhaps due to defects in erythrocyte cell maturation in the bone marrow. In support of this notion, MEPs in the bone marrow of compound mutant mice were increased and there were more erythroid progenitors present in the spleen, which most likely contributed to the splenomegaly in these mice.
The disease course of JMML also exhibits pronounced splenomegaly, sometimes even in the absence of highly elevated WBC count. It has been previously reported that mice with Dnmt3a −/− combined with Kras G12D/+ mutation, another common mutation found in JMML patients, developed stress erythropoiesis in the spleen [14] . Perhaps one reason JMML patients develop extreme splenomegaly is compensatory splenic erythropoiesis, as observed in the Dnmt3a
+/−
;D61Y mice in this study. Because DNMT3A and PTPN11 mutations are found in combination in AML and JMML patients, our double mutant mice provide a novel clinically relevant model for developing and evaluating therapies for myeloid leukemia. In AML, the presence of a DNMT3A mutation led to significantly shortened overall survival [1] . For JMML, a disease with poor prognosis, there is currently no established decision-making process for determining which patients would be candidates for experimental therapies. However, it is known that the number of mutations present at diagnosis is strongly correlated with survival when comparing patients who have 0-1 mutations to those with 2 or more mutations [12] . Further work must be done to find the importance of having specifically the DNMT3A and PTPN11 genes mutated together, but these are two commonly mutated genes in myeloid leukemia that we have now shown leads to accelerated disease.
The mechanism of how Dnmt3a loss cooperates with driver mutations to accelerate disease progression is still unknown, but our Dnmt3a
;D61Y mouse model will be useful to explore this question. We speculate that the changes in methylation caused by reduced DNMT3A activity may lead to epigenetic changes that alter the normal transcription of tumor suppressor genes needed to dampen Shp2 signaling. Future work doing a genomewide transcriptional analysis would help to elucidate the mechanism of enhanced myeloid leukemia observed in the double mutant mice.
METHODS
Animal husbandry
Mice with a conditional mutant Shp2 allele, LSLShp2 D61Y/+ , have been previously described [9] . Mice with a conditional knockout Dnmt3a allele have been previously described [13] . Expression of the D61Y mutation, the Dnmt3a mutation, and Mx1-cre were confirmed by genotyping. Three intraperitoneal injections of 300ug polyI:polyC were administered concurrently to mice of each cohort. Mice were housed and bred in accordance with the Institutional Animal Care and Use Committee of the Indiana University School of Medicine.
Flow cytometry
Cell suspensions were incubated for 5 minutes with 10% rat serum (MP Biomedicals) and 0.2% BSA (Roche) in PBS, then stained for 30 minutes at 4°C with biotinylated lineage markers (Mac1, Gr1, CD4, CD8, B220, Ter119, IL7Rα, CD19, and CD3 with streptavidin PerCPcy5.5 as secondary), anti-Sca1-PE, anti-cKit-APC, anti-CD34-FITC, anti-CD16/32-PEcy7, anti-Gr1-FITC, anti-Mac1-APC, biotinylated anti-CD4 and anti-CD8 (with streptavidin APC as secondary), anti-B220-PE, anti-CD71-PE, and/or anti-CD36-APC (eBioscience and BD Biosciences). The analyzer used for flow cytometry was the BD LSR II and data was analyzed using CellQuest.
Complete blood counts
Peripheral blood was collected from the saphenous vein of mice and complete blood counts were measured using a Hemavet 950 (Drew Scientific Group).
Statistical calculations
GraphPad was used to perform the unpaired, twotailed, Student's t-tests.
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